drugset / Trial / NCT02331433

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

NCT02331433 ↗

Phase 1 Completed 58 enrolled CoMentis Alpharmagen, Inc. · collab
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.

Timeline

Start
2014-12
Primary completion
2015-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject APN1125 Unknown — Oral

Indications